282 related articles for article (PubMed ID: 21926667)
1. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.
Bernstein DI; Malkin E; Abughali N; Falloon J; Yi T; Dubovsky F;
Pediatr Infect Dis J; 2012 Feb; 31(2):109-14. PubMed ID: 21926667
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
Belshe RB; Newman FK; Anderson EL; Wright PF; Karron RA; Tollefson S; Henderson FW; Meissner HC; Madhi S; Roberton D; Marshall H; Loh R; Sly P; Murphy B; Tatem JM; Randolph V; Hackell J; Gruber W; Tsai TF
J Infect Dis; 2004 Dec; 190(12):2096-103. PubMed ID: 15551207
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
Belshe RB; Newman FK; Tsai TF; Karron RA; Reisinger K; Roberton D; Marshall H; Schwartz R; King J; Henderson FW; Rodriguez W; Severs JM; Wright PF; Keyserling H; Weinberg GA; Bromberg K; Loh R; Sly P; McIntyre P; Ziegler JB; Hackell J; Deatly A; Georgiu A; Paschalis M; Wu SL; Tatem JM; Murphy B; Anderson E
J Infect Dis; 2004 Feb; 189(3):462-70. PubMed ID: 14745704
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.
Malkin E; Yogev R; Abughali N; Sliman J; Wang CK; Zuo F; Yang CF; Eickhoff M; Esser MT; Tang RS; Dubovsky F
PLoS One; 2013; 8(10):e77104. PubMed ID: 24204744
[TBL] [Abstract][Full Text] [Related]
5. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
[TBL] [Abstract][Full Text] [Related]
6. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.
Tang RS; Spaete RR; Thompson MW; MacPhail M; Guzzetta JM; Ryan PC; Reisinger K; Chandler P; Hilty M; Walker RE; Gomez MM; Losonsky GA
Vaccine; 2008 Nov; 26(50):6373-82. PubMed ID: 18822334
[TBL] [Abstract][Full Text] [Related]
7. Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccine.
Yang CF; Wang CK; Malkin E; Schickli JH; Shambaugh C; Zuo F; Galinski MS; Dubovsky F; ; Tang RS
Vaccine; 2013 Jun; 31(26):2822-7. PubMed ID: 23602668
[TBL] [Abstract][Full Text] [Related]
8. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.
Englund JA; Karron RA; Cunningham CK; Larussa P; Melvin A; Yogev R; Handelsman E; Siberry GK; Thumar B; Schappell E; Bull CV; Chu HY; Schaap-Nutt A; Buchholz U; Collins PL; Schmidt AC;
Vaccine; 2013 Nov; 31(48):5706-12. PubMed ID: 24103895
[TBL] [Abstract][Full Text] [Related]
9. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.
Gomez M; Mufson MA; Dubovsky F; Knightly C; Zeng W; Losonsky G
Pediatr Infect Dis J; 2009 Jul; 28(7):655-8. PubMed ID: 19483659
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants.
Bernstein DI; Falloon J; Yi T
Vaccine; 2011 Sep; 29(40):7042-8. PubMed ID: 21782874
[TBL] [Abstract][Full Text] [Related]
11. Genetic stability of RSV-F expression and the restricted growth phenotype of a live attenuated PIV3 vectored RSV vaccine candidate (MEDI-534) following restrictive growth in human lung cells.
Nelson CL; Tang RS; Stillman EA
Vaccine; 2013 Aug; 31(36):3756-62. PubMed ID: 23623857
[TBL] [Abstract][Full Text] [Related]
12. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
[TBL] [Abstract][Full Text] [Related]
13. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL
J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245
[TBL] [Abstract][Full Text] [Related]
14. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
15. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.
Lee MS; Greenberg DP; Yeh SH; Yogev R; Reisinger KS; Ward JI; Blatter MM; Cho I; Holmes SJ; Cordova JM; August MJ; Chen W; Mehta HB; Coelingh KL; Mendelman PM
J Infect Dis; 2001 Oct; 184(7):909-13. PubMed ID: 11509996
[TBL] [Abstract][Full Text] [Related]
16. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
[TBL] [Abstract][Full Text] [Related]
17. Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.
Tang RS; MacPhail M; Schickli JH; Kaur J; Robinson CL; Lawlor HA; Guzzetta JM; Spaete RR; Haller AA
J Virol; 2004 Oct; 78(20):11198-207. PubMed ID: 15452239
[TBL] [Abstract][Full Text] [Related]
18. Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.
Murphy BR; Collins PL
Bull World Health Organ; 1997; 75(4):307-13. PubMed ID: 9342889
[TBL] [Abstract][Full Text] [Related]
19. Current status of vaccines for parainfluenza virus infections.
Sato M; Wright PF
Pediatr Infect Dis J; 2008 Oct; 27(10 Suppl):S123-5. PubMed ID: 18820572
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with respiratory syncytial virus vaccines.
Piedra PA
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
